Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.1%. By the end of trading, Onyx Pharmaceuticals rose $6.53 (5.6%) to $123.49 on heavy volume. Throughout the day, 23,185,420 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 2,335,500 shares. The stock ranged in a price between $123.40-$123.70 after having opened the day at $123.65 as compared to the previous trading day's close of $116.96. Other companies within the Drugs industry that increased today were:
), up 18.8%,
), up 15.2%,
), up 13.7% and
), up 12.2%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $8.6 billion and is part of the health care sector. Shares are up 55.7% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.
TheStreet Ratings rates Onyx Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.
- You can view the full Onyx Pharmaceuticals Ratings Report.
On the negative front,
), down 40.6%,
), down 13.5%,
), down 9.1% and
), down 9.1% , were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.